Study to Assess Adverse Events and the Movement of Oral Venetoclax Tablet Through the Body of Female Participants Aged 18-75 Years With Impaired Renal Function

Overview

Renal insufficiency is common in participants with blood cancers. The main objective of this study is to evaluate adverse events and movement of oral venetoclax tablets through the body of female participants with severe normal renal function and those with end stage renal disease (ESRD) requiring hemodialysis. Venetoclax is an investigational drug being developed for the treatment of various hematologic malignancies. Study doctors put the participants in 1 of 2 groups, called treatment arms. Each group receives a different treatment. Approximately 12 female participants between 18 and 75 years, with Body Mass Index (BMI) between 18 to 42 kg/m2 will be enrolled in approximately 4 sites across the world. Participants with normal renal function will receive single dose of oral venetoclax tablet. Participants with ESRD will receive oral venetoclax tablets just prior to hemodialysis (Period 1 Day 1) and between dialysis days (Period 2 Day 1), doses in the two periods will be separated by at least 7 days. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood and urine tests, checking for side effects.

Full Title of Study: “Evaluation of the Pharmacokinetics and Safety of Venetoclax in Subjects With Impaired Renal Function”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Basic Science
    • Masking: None (Open Label)
  • Study Primary Completion Date: August 16, 2022

Interventions

  • Drug: Venetoclax
    • Oral Tablet

Arms, Groups and Cohorts

  • Experimental: Group 1: Participants With Normal Renal Function
    • Participants with normal renal function will receive single dose of venetoclax on Day 1.
  • Experimental: Group 2: Participants With End Stage Renal Disease
    • Participants with end stage renal disease (ESRD) will receive single dose of venetoclax on Period 1 Day 1 and Period 2 Day 1 (Each period is 3 days separated by 7-day washout period).

Clinical Trial Outcome Measures

Primary Measures

  • Percentage of Participants With Adverse Events (AEs)
    • Time Frame: Up to approximately 38 days
    • An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above.
  • Maximum Plasma Concentration (Cmax) of Venetoclax (Groups 1,2)
    • Time Frame: Up to Day 6
    • Maximum Plasma Concentration (Cmax) of Venetoclax.
  • Time to Cmax (Tmax) of Venetoclax (Groups 1,2)
    • Time Frame: Up to Day 6
    • Time to Cmax (Tmax) of Venetoclax.
  • Area Under the Plasma Concentration-time Curve over time from time 0 to 48 hours (AUC0-48) of Venetoclax (Groups 1,2)
    • Time Frame: Up to Day 6
    • Area Under the Plasma Concentration-time Curve over time from time 0 to 48 hours (AUC0-48).
  • Pre-dose Unbound Fraction (fu) of Venetoclax in Plasma (Groups 1,2)
    • Time Frame: Day 1
    • Unbound Fraction (fu) of Venetoclax in Plasma.
  • Dialysis Clearance (CLdialysis) (Group 2)
    • Time Frame: Day 1
    • Dialysis Clearance (CLdialysis) is calculated in participants undergoing hemodialysis in Period 1.
  • Unbound Fraction Pre-dialysis (fu,predialysis) of Venetoclax in Plasma (Group 2)
    • Time Frame: Day 1
    • Unbound fraction pre-dialysis (fu,predialysis) of venetoclax in plasma is calculated in participants undergoing hemodialysis in Period 1.
  • Unbound Fraction Post-dialysis (fu,postdialysis) of Venetoclax in Plasma (Group 2)
    • Time Frame: Day 1
    • Unbound fraction post-dialysis (fu,postdialysis) of venetoclax in plasma is calculated in participants undergoing hemodialysis in Period 1.

Participating in This Clinical Trial

Inclusion Criteria

  • Body mass index (BMI) between 18.0 and 42.0 kg/m2. – Postmenopausal or permanently surgically sterile (bilateral oophorectomy, bilateral salpingectomy, or hysterectomy). – Women of childbearing potential, practicing at least 2 protocol specified methods of birth control that are effective from at least 30 days before starting study drug through at least 30 days after the last dose of any study drug. – Group 1 only: Must be in general good health based upon the results of a medical history, physical examination, and 12-lead electrocardiogram (ECG) with normal Glomerular Filtration Rate (GFR) at Screening. – Group 2 only: Stable condition and acceptable for study participation based upon the results of a medical history, physical examination, laboratory profile, and ECG. Participant with end stage renal disease (ESRD) requiring dialysis on hemodialysis must have been receiving hemodialysis for at least 1 month. Exclusion Criteria:

  • Participants on a strict vegetarian or vegan diet.

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: 75 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • AbbVie
  • Collaborator
    • Roche-Genentech
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • ABBVIE INC., Study Director, AbbVie

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.